NICOYA年衍药业
/
Back to newsroom
Research Highlights

WCN Express: Extended-Release Calcifediol Slows Chronic Kidney Disease Progression

Reported at the World Congress of Nephrology (WCN 2026) in Yokohama, a post-hoc analysis of a Chinese phase 3 bridging study showed that among patients with secondary hyperparathyroidism (SHPT) receiving extended-release calcifediol (ERC), those whose intact parathyroid hormone (iPTH) fell by >=30% from baseline had a significantly slower decline in eGFR than non-responders (-2.4 +/- 3.8 vs -5.1 +/- 5.3 mL/min/1.73 m2, p=0.036), with no effect of sustained iPTH reduction on safety parameters - consistent with findings from US studies.

Research Highlights

Preface

The World Congress of Nephrology (WCN 2026), one of the most influential nephrology meetings worldwide and organized by the International Society of Nephrology (ISN), is being held in Yokohama, Japan. The congress is organized around four core themes - optimizing kidney health, the interconnectedness and wholeness of the kidney, safeguarding kidney health, and smart kidneys - which are intended to guide the future of global kidney care and treatment. A study from China was reported at this year's congress [1]: "Extended-release calcifediol, on top of parathyroid hormone reduction, slows chronic kidney disease progression in Chinese patients with secondary hyperparathyroidism".

1 Background

Chronic kidney disease (CKD) is a global public health problem, with incidence, prevalence and healthcare costs continuing to rise. By 2050, CKD is projected to become the fifth leading cause of age-standardized mortality worldwide [2]. Secondary hyperparathyroidism (SHPT) develops as CKD progresses, and persistently elevated parathyroid hormone (PTH) may be nephrotoxic and is associated with earlier initiation of dialysis [3,4]. Post-hoc analyses of two phase 3 studies conducted in the United States showed that extended-release calcifediol (ERC) produced a sustained reduction of >=30% from baseline (BL) in elevated intact PTH (iPTH), which was associated with a slower decline in estimated glomerular filtration rate (eGFR) in patients with stage 3-4 CKD and SHPT [5]. This post-hoc analysis of a Chinese phase 3 bridging study [1] aimed to investigate whether effective iPTH reduction also slows CKD progression in Chinese patients with SHPT receiving ERC.

2 Methods

The Chinese phase 3 bridging study enrolled 100 patients with stage 3 or 4 CKD and SHPT. Key inclusion criteria included eGFR >=15 to <60 mL/min/1.73 m2, plasma iPTH >=85 pg/mL, and serum total 25-hydroxyvitamin D (25D) <30 ng/mL; 67 subjects received ERC for 26 consecutive weeks. eGFR was assessed at weeks 13 and 26 of treatment. A total of 60 subjects had eGFR measured at both weeks 13 and 26 and were grouped by iPTH response* during the efficacy assessment period (EAP, the last 6 weeks of treatment, i.e. weeks 20-26) into responders and non-responders; eGFR change from baseline (CFB) was compared between the two groups using the t-test. Baseline characteristics and demographics of the 60 subjects are shown in Table 1.

*Response: a reduction of >=30% from baseline in plasma iPTH during the EAP (defined as the last 6 weeks of treatment).

3 Results

Among the 60 participants, by the EAP mean (SD) 25D had increased from 17 +/- 5 ng/mL at baseline to 96 +/- 25 ng/mL (p<0.001), and iPTH had decreased from 160.1 +/- 67.9 pg/mL to 120.3 +/- 69.8 pg/mL (p<0.001). Baseline eGFR was 23.1 +/- 6.4 mL/min/1.73 m2 in responders (n=34) and similar in non-responders (n=26; 23.0 +/- 8.1 mL/min/1.73 m2). The rate of eGFR decline in non-responders (eGFR CFB: -5.1 +/- 5.3 mL/min/1.73 m2) was more than twice that in responders (eGFR CFB: -2.4 +/- 3.8 mL/min/1.73 m2) (p=0.036), see Figure 1. Changes in serum phosphorus did not differ significantly between the two groups (CFB 0.2 +/- 0.4 vs 0.4 +/- 0.6 mg/mL, p=0.13). Serum calcium increased slightly from baseline in responders (CFB 0.2 +/- 0.2 mg/dL), whereas no increase was observed in non-responders (CFB 0.0 +/- 0.2 mg/dL). Sustained iPTH reduction had no effect on safety parameters.

Figure 1. Relationship between the magnitude of parathyroid hormone reduction and the change in glomerular filtration rate.

4 Conclusions

In Chinese patients with stage 3-4 CKD and SHPT treated with ERC, those who achieved an effective iPTH reduction of >=30% had a slower decline in eGFR with no safety concerns; that is, extended-release calcifediol may slow CKD progression to some extent, consistent with findings from US studies [1,5].

Extended-release calcifediol (ERC)

Extended-release calcifediol (ERC) was approved by the US Food and Drug Administration in 2016 and marketed as Rayaldee(R) for the treatment of secondary hyperparathyroidism (SHPT) and vitamin D insufficiency in adults with stage 3-4 CKD [6]. A Chinese phase 3 clinical trial of ERC in patients with stage 3-4 CKD, SHPT and vitamin D insufficiency also produced positive results [7]; the trial met its primary endpoint, confirming that ERC effectively corrects vitamin D insufficiency and controls iPTH while offering a favorable safety and convenience profile, filling the clinical gap for this indication in China, where no approved therapy had been available for this population.

Comparison of the effects of different vitamin D treatment regimens on blood, bone and mineral parameters [6]

ERC significantly and durably suppresses plasma parathyroid hormone (PTH) in patients with CKD. By slowly releasing calcifediol, it avoids abrupt increases in serum calcifediol and calcitriol levels. ERC has been shown to effectively improve vitamin D insufficiency and control PTH without markedly disturbing calcium-phosphorus homeostasis, providing clinicians and patients with a new treatment option [6,7].

References

1. WCN26-AB-6077: Ming Fang, Yan Hao, Huijuan Mao, et al. Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-release Calcifediol Slows Chronic Kidney Disease Progression in Chinese Secondary Hyperparathyroidism Patients: A Post-hoc Analysis.

2. William G Herrington, Parminder K Judge, Morgan E Grams, et al. Chronic kidney disease. Lancet. 2026; 407(10523): 90-104.

3. Eduardo J Duque, Rosilene M Elias, Rosa M A Moyses. Parathyroid Hormone: A Uremic Toxin. Toxins (Basel). 2020; 12(3): 189.

4. Milica Bozic, Juan M Diaz-Tocados, Marcelino Bermudez-Lopez, et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant. 2022; 37(4): 663-672.

5. Charles W Bishop, Akhtar Ashfaq, Stephen A Strugnell, et al. Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients. Am J Nephrol. 2024; 27:1-10.

6. Stuart M Sprague, Stephen A Strugnell, Charles W Bishop. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Rev Endocrinol Metab. 2017; 12(5):289-301.

7. 2025 ASN PO1192: Ming Fang, Yan Hao, Huijuan Mao, et al. Extended-Release Calcifediol (ERC) For Secondary Hyperparathyroidism (SHPT) in Chinese Patients with Stage 3 and 4 Chronic Kidney Disease (CKD): A Phase 3 Trial.

View original source年衍药业(微信公众号) ↗